In 2024, the iShares Biotechnology ETF (NASDAQ:IBB) is up just over 1.5%. If you’re looking for steady, dividend-paying stocks, you can find a number of biotech stocks to buy from the holdings in this fund.However, if you’re looking for the chance to turn a modest investment into, perhaps, generational wealth, the list becomes narrower and carries a lot more risk. But it’s exactly that risk/reward relationship that makes it an attractive sector for speculative investors.  Investing in biotech stocks that ca ...

Biotech stocks to buy now reflect a more dynamic shift in investor focus of late.Over the past few years, the biotech space attracted plenty of investor interest, driven by the Covid-19 pandemic. Global vaccine sales for the crippling virus were upwards of $142 billion from 2020 to 2023. The vaccine rollout was hugely successful across the globe, especially in countries like the U.S., U.K. and Germany.Now, a couple of years after the lifting of lockdown restrictions worldwide, the buzz around vaccines has q ...

文章核心观点 - 尽管CRISPR Therapeutics的股票在过去一年中一直呈现横盘走势,但短期内可能会迎来更好的日子[1] - CRISPR Therapeutics成功推进其基因编辑疗法Casgevy通过临床试验,并在多个地区获得监管批准,包括美国、英国、欧盟和沙特阿拉伯[3] - CRISPR Therapeutics正与生物科技巨头Vertex Pharmaceuticals合作,华尔街预计Casgevy未来将达到每年10亿美元的销售额[4] - 尽管如此,CRISPR Therapeutics的股价在过去12个月中几乎没有变动[4] 公司相关 - CRISPR Therapeutics正在开发其他管线产品,涉及肿瘤、自身免疫、糖尿病和心血管疾病等领域[8] - Casgevy的商业化需要一年或更长时间才能真正起步,这需要投资者的耐心[8] - Casgevy作为一种基因疗法,其给药过程复杂,需要专业设施和专业知识,这意味着在最初几个季度不会有太高的渗透率[10][11] 行业相关 - 创新型股票为投资者带来了双刃剑,既有巨大的潜力,也有重大的风险[2] - 将概念转化为可商业化的产品或服务是一个复杂、耗时且资金密集的过程,监管障碍、技术挫折或市场需求的变化都可能阻碍最有前景的创新[2]

In the world of investing, biotech stocks represent a unique blend of high risk and high reward. After a period of volatility in the broader markets in 2022 and 2023, biotech stocks are now drawing attention for their potential to deliver substantial long-term returns.The global biotechnology market, valued at $1.2 trillion in 2022, is projected to grow to $3.9 trillion by 2031. Key drivers for growth include increasing R&D activities, government funding and rising demand. New biotechnology products can add ...

Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body. All to treat cancers, blood issues, blindness, cystic fibrosis, and muscular dystrophy. All of which is creating substantial opportunities for some of the leading gene editing stocks.What’s more exciting is companies like Profluent Bio “leveraged artificial intelligence to design an open-source gene editor called OpenCRISPR-1, demonstrating the technology can be used to creat ...

The latest trading session saw CRISPR Therapeutics AG (CRSP) ending at $56.63, denoting a +1.22% adjustment from its last day's close. The stock exceeded the S&P 500, which registered a gain of 0.16% for the day. Elsewhere, the Dow saw an upswing of 0.04%, while the tech-heavy Nasdaq appreciated by 0.49%.Heading into today, shares of the company had gained 2.02% over the past month, lagging the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22% in that time.The investment community will be payin ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this company have returned +1.8% over the past month versus the Zacks S&P 500 composite's +2.7% change. The Zacks Medical - Biomedical and Genetics industry, to which CRISPR Therapeutics belongs, has lost 0.5% over this period. Now the key question is: Where could the stock be h ...

CRISPR Therapeutics AG (CRSP) closed at $59.60 in the latest trading session, marking a -1.6% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.25%. Elsewhere, the Dow gained 0.77%, while the tech-heavy Nasdaq lost 0.79%.The company's shares have seen an increase of 6.64% over the last month, surpassing the Medical sector's gain of 0.03% and the S&P 500's gain of 3.59%.Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming ea ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Company Conference Call June 11, 2024 9:20 AM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good afternoon everyone, thank you for joining us. Really pleased to have Sam Kulkarni, CEO of CRISPR Therapeutics here with us. Sam, perhaps to start here, you have a couple of verticals - you have cancer, ex-vivo non-cancer, regenerative medicine, and in vivo verticals. Can you discus ...

会议主要讨论的核心内容 - 公司的投资组合包括癌症、体外非癌症、再生医学和体内基因编辑等多个垂直领域 [3][4][5][6][7] - 公司在基因编辑技术的持续创新和改进上投入了大量资源,建立了专门的CRISPR X团队 [9][10][11][12] - 公司在交付技术方面主要关注脂质纳米颗粒(LNP),并取得了在肝脏以外器官如眼睛的递送突破 [13][14][15] - 公司首个获批上市的基因编辑产品Casgevy(与Vertex合作)的上市情况良好,全球需求旺盛,且获得较好的支付报销 [16][17][18][19][20][21][22][23] - 公司正在努力开发更加温和的预处理方案,以及体内造血干细胞编辑技术,以进一步提升Casgevy的临床应用 [28][29][30][31] - 公司的体内基因编辑平台正在开展心血管疾病相关靶点的临床试验,有望在今年内获得首批数据 [33][34][35] - 公司的自身免疫疾病业务发展迅速,有望凭借其独特的同种异体CAR-T疗法在该领域取得领先地位 [37][38][39][40][41][42] - 公司的肿瘤业务持续优化,预计今年将有新一代CAR-T产品的临床数据发布,有望进一步提升公司在该领域的竞争力 [45][46][47][48][50] - 公司的再生医学业务,特别是1型糖尿病项目,也是公司的重点发展方向之一 [53][54][55] 问答环节重要的提问和回答 问题1 **Salveen Richter 提问** 公司如何在不同垂直领域间进行资本配置和R&D协同? [2] **Sam Kulkarni 回答** 公司根据CRISPR技术的优势和可以产生最大影响的疾病领域来确定投资组合 [3][4][5][6][7][8] 公司建立了专门的CRISPR X团队持续推进技术创新 [9][10][11][12] 问题2 **Salveen Richter 提问** 公司如何看待Casgevy的商业化情况,包括患者和医生反馈、渗透率以及未来优化的机会? [16][27] **Sam Kulkarni 回答** Casgevy的上市反响良好,全球需求旺盛,获得较好的支付报销支持 [17][18][19][20][21][22][23] 公司正在努力开发更加温和的预处理方案,以及体内造血干细胞编辑技术,以进一步提升Casgevy的临床应用 [28][29][30][31] 问题3 **Salveen Richter 提问** 公司的体内基因编辑平台在心血管疾病领域的进展如何,首批数据意味着什么? [32] **Sam Kulkarni 回答** 公司的体内基因编辑平台正在开展心血管疾病相关靶点的临床试验,有望在今年内获得首批数据,这将为公司后续在该领域的发展奠定基础 [33][34][35]